Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 7,600 shares at $22.15 ($169K) on 2024-12-27, disclosed to the SEC on 2024-12-31.
Scheduled sale ($169k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.15 | 3,350 | $74K | 44.0% |
| 2 | $22.15 | 3,350 | $74K | 44.0% |
| 3 | $22.51 | 900 | $20K | 12.0% |
| Total | $22.19 avg | 7,600 | $169K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |